Document is current
Any future updates will be listed below
-
Authors
Bethe, Ullrich https://orcid.org/0000-0001-9979-1671
Pana, Zoi D. https://orcid.org/0000-0002-5893-1081
Drosten, Christian https://orcid.org/0000-0001-7923-0519
Goossens, Herman https://orcid.org/0000-0003-4891-4031
König, Franz https://orcid.org/0000-0002-6893-3304
Marchant, Arnaud https://orcid.org/0000-0002-0007-382X
Molenberghs, Geert https://orcid.org/0000-0002-6453-5448
Posch, Martin https://orcid.org/0000-0001-8499-8573
Van Damme, Pierre https://orcid.org/0000-0002-8642-1249
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 4 July 2024
First Online: 17 July 2024
Declarations
:
: Ullrich Bethe, Zoi D. Pana, Christian Drosten, Franz König, Herman Goossens, Arnaud Marchant, Geert Molenberghs, Martin Posch: no conflicts declared. Pierre Van Damme (PVD): Grant from CEPI-HERA for COVID-19 vaccine assessment, payments made to PVD’s institution. Participation on a Data Safety Monitoring Board or Advisory Board of Janssen Vaccines, no payments received, and of LG Chem, payments made to PVD’s institution. Oliver A. Cornely (OAC): Grants or contracts from BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis, payments made to OAC’s institution. Consulting fees from Abbvie, AiCuris, Basilea, Biocon, Cidara, Seqirus, Gilead, GSK, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Mundipharma, Noxxon, Octapharma, Pardes, Partner Therapeutics, Pfizer, PSI, Scynexis, Seres, payments made to OAC. Payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, Abbvie, Akademie für Infektionsmedizin, Al-Jazeera Pharmaceuticals/Hikma, amedes, AstraZeneca, Biotoscana Farma, Deutscher Ärzteverlag, Gilead, GSK, Grupo Biotoscana/United Medical/Knight, Medscape/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, streamedup!, Touch Independent, Vitis, payments made to OAC. Payment for expert testimony Cidara, payments made to OAC. Patents planned, issued or pending: Patent US18/562644, “Geschlossene Inkubationssysteme mit verbessertem Atemwegszugang für Untersuchungsvorrichtungen”, DE 10 2021 113 007.7), filed by the University of Cologne and listing OAC as one of three inventors. Participation on a Data Safety Monitoring Board or Advisory Board of Boston Strategic Partners, Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Shionogi, The Prime Meridian Group, payments made to OAC.
